fbpx

News

Lundbeckfonden Ventures News

Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease BOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014. Acacia Pharma Group plc Interim Results for the Six Months ended 30 June 2020 US approval for BARHEMSYS® for postoperative nausea & vomiting (PONV) US approval of BYFAVO™ for procedural sedation Strategic agreement with Cosmo Technologies providing funding for US...
EO2401 combines three ‘OncoMimics’ designed to trigger the immune system into recognizing tumor cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response First patient dosed in Phase 1/2 (‘ROSALIE’) trial investigating EO2401 Paris, France and Cambridge, MA, USA – July 30, 2020 ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 27 July 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), announces that the US Food and Drug Administration (FDA) has approved of a second supplier for...
–    FDA has agreed to key aspects of the clinical program, including the primary endpoint for the single pivotal phase 3 study –    There are approximately 175,000 and 150,000 ESKD patients with PAD in the USA and Europe respectively with no approved treatments Palma, Spain and San Diego, USA, 20 July 2020 – Sanifit, a clinical-stage biopharmaceutical company developing...
Cambridge, UK and Indianapolis, US – 16 July 2020: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that application has been made to Euronext Brussels...
Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 15 July 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical...
After Discussions with FDA, NDA Submission Planned for 3Q 2020 under Accelerated Approval Pathway  Reltecimod in conjunction with currently available standard of care demonstrated a significant difference in the percentage of patients who achieved resolution of organ dysfunction/failure by Day 14 versus standard of care alone  Resolution of organ dysfunction/failure at Day 14...
Financing co-led by Ysios Capital and INKEF Capital, joined by Lundbeckfonden Ventures, LSP, and existing investors BioGeneration Ventures and InnovationQuarter • Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-C001, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program Leiden, The Netherlands,...
1 2 3 4 68

Lundbeckfonden Ventures

News

Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
23. September 2020
Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma
11. September 2020
Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors
9. September 2020